A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Clinical trial NCT05552976 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05552976
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-10
- Primary completion
- 2026-07-18
- Enrollment
- 606
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.